Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 174


LABA/LAMA fixed-dose combinations in patients with COPD: a systematic review.

Rogliani P, Calzetta L, Braido F, Cazzola M, Clini E, Pelaia G, Rossi A, Scichilone N, Di Marco F.

Int J Chron Obstruct Pulmon Dis. 2018 Oct 4;13:3115-3130. doi: 10.2147/COPD.S170606. eCollection 2018.


Once daily long-acting beta2-agonists and long-acting muscarinic antagonists in a combined inhaler versus placebo for chronic obstructive pulmonary disease.

Maqsood U, Ho TN, Palmer K, Eccles FJ, Munavvar M, Wang R, Crossingham I, Evans DJ.

Cochrane Database Syst Rev. 2019 Mar 6;3:CD012930. doi: 10.1002/14651858.CD012930.pub2.


Impact of ICS/LABA and LABA/LAMA FDCs on functional and clinical outcomes in COPD: A network meta-analysis.

Calzetta L, Di Marco F, Blasi F, Cazzola M, Centanni S, Micheletto C, Rossi A, Rogliani P.

Pulm Pharmacol Ther. 2019 Dec;59:101855. doi: 10.1016/j.pupt.2019.101855. Epub 2019 Oct 19.


Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis.

Kew KM, Dias S, Cates CJ.

Cochrane Database Syst Rev. 2014 Mar 26;(3):CD010844. doi: 10.1002/14651858.CD010844.pub2. Review.


Comparative efficacy of fixed-dose combinations of long-acting muscarinic antagonists and long-acting β2-agonists: a systematic review and network meta-analysis.

Schlueter M, Gonzalez-Rojas N, Baldwin M, Groenke L, Voss F, Reason T.

Ther Adv Respir Dis. 2016 Apr;10(2):89-104. doi: 10.1177/1753465815624612. Epub 2016 Jan 8. Review.


Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD).

Horita N, Goto A, Shibata Y, Ota E, Nakashima K, Nagai K, Kaneko T.

Cochrane Database Syst Rev. 2017 Feb 10;2:CD012066. doi: 10.1002/14651858.CD012066.pub2. Review.


Efficacy and safety of direct switch to indacaterol/glycopyrronium in patients with moderate COPD: the CRYSTAL open-label randomised trial.

Vogelmeier CF, Gaga M, Aalamian-Mattheis M, Greulich T, Marin JM, Castellani W, Ninane V, Lane S, Nunez X, Patalano F, Clemens A, Kostikas K; CRYSTAL study investigators.

Respir Res. 2017 Jul 18;18(1):140. doi: 10.1186/s12931-017-0622-x.


Comparative efficacy of inhaled medications (ICS/LABA, LAMA, LAMA/LABA and SAMA) for COPD: a systematic review and network meta-analysis.

Aziz MIA, Tan LE, Wu DB, Pearce F, Chua GSW, Lin L, Tan PT, Ng K.

Int J Chron Obstruct Pulmon Dis. 2018 Oct 9;13:3203-3231. doi: 10.2147/COPD.S173472. eCollection 2018.


LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis.

Rodrigo GJ, Price D, Anzueto A, Singh D, Altman P, Bader G, Patalano F, Fogel R, Kostikas K.

Int J Chron Obstruct Pulmon Dis. 2017 Mar 17;12:907-922. doi: 10.2147/COPD.S130482. eCollection 2017. Review.


Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease.

Farne HA, Cates CJ.

Cochrane Database Syst Rev. 2015 Oct 22;(10):CD008989. doi: 10.1002/14651858.CD008989.pub3. Review.


Dual bronchodilation in COPD: lung function and patient-reported outcomes - a review.

Price D, Østrem A, Thomas M, Welte T.

Int J Chron Obstruct Pulmon Dis. 2016 Dec 30;12:141-168. doi: 10.2147/COPD.S116719. eCollection 2017. Review.


Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network meta-analysis.

Oba Y, Keeney E, Ghatehorde N, Dias S.

Cochrane Database Syst Rev. 2018 Dec 3;12:CD012620. doi: 10.1002/14651858.CD012620.pub2.


A Systematic Review With Meta-Analysis of Dual Bronchodilation With LAMA/LABA for the Treatment of Stable COPD.

Calzetta L, Rogliani P, Matera MG, Cazzola M.

Chest. 2016 May;149(5):1181-96. doi: 10.1016/j.chest.2016.02.646. Epub 2016 Feb 26. Review.


Indacaterol/glycopyrronium versus salmeterol/fluticasone in Asian patients with COPD at a high risk of exacerbations: results from the FLAME study.

Wedzicha JA, Zhong N, Ichinose M, Humphries M, Fogel R, Thach C, Patalano F, Banerji D.

Int J Chron Obstruct Pulmon Dis. 2017 Jan 19;12:339-349. doi: 10.2147/COPD.S125058. eCollection 2017.


Real-life effectiveness of indacaterol-glycopyrronium after switching from tiotropium or salmeterol/fluticasone therapy in patients with symptomatic COPD: the POWER study.

Kaplan A, Chapman KR, Anees SM, Mayers I, Rochdi D, Djandji M, Préfontaine D, McIvor A.

Int J Chron Obstruct Pulmon Dis. 2019 Jan 18;14:249-260. doi: 10.2147/COPD.S185485. eCollection 2019.


Efficacy and safety of indacaterol/glycopyrronium fixed-dose combination in mild-to-moderate COPD patients symptomatic on tiotropium in Korea: study protocol for a randomized controlled trial.

Rhee CK, Park HY, Park JW, Lee JH, Kim TH, Lee SW, Jung JY, Kim S, Hwang YI, Jung KS.

Trials. 2017 Feb 22;18(1):80. doi: 10.1186/s13063-017-1800-3.


Role of dual bronchodilators in COPD: A review of the current evidence for indacaterol/glycopyrronium.

Ficker JH, Rabe KF, Welte T.

Pulm Pharmacol Ther. 2017 Aug;45:19-33. doi: 10.1016/j.pupt.2017.04.002. Epub 2017 Apr 4. Review.


Efficacy and safety of the direct switch to indacaterol/glycopyrronium from salmeterol/fluticasone in non-frequently exacerbating COPD patients: The FLASH randomized controlled trial.

Frith PA, Ashmawi S, Krishnamurthy S, Gurgun A, Hristoskova S, Pilipovic V, Hamann AM, Backer A, Olsson P, Kostikas K, Diaz DV; FLASH Investigators.

Respirology. 2018 Dec;23(12):1152-1159. doi: 10.1111/resp.13374. Epub 2018 Aug 3.


Indacaterol/glycopyrronium reduces the risk of clinically important deterioration after direct switch from baseline therapies in patients with moderate COPD: a post hoc analysis of the CRYSTAL study.

Greulich T, Kostikas K, Gaga M, Aalamian-Mattheis M, Lossi NS, Patalano F, Nunez X, Pagano VA, Fogel R, Vogelmeier CF, Clemens A.

Int J Chron Obstruct Pulmon Dis. 2018 Apr 16;13:1229-1237. doi: 10.2147/COPD.S159732. eCollection 2018.

Supplemental Content

Support Center